Delivery Of Drugs For A Non-Commercial Clinical Trial For The Experimental Arm Of Avo-Cll Financed By The Medical Research Agency As Part Of The Project Entitled "Avo-Cll Study: A Multicenter, Randomized, Open-Label, Phase 3 Study Comparing The Efficacy And Safety Of Acalabrutinib In Combination With Obinutuzumab Versus Venetoclax In Combination With Obinutuzumab In The First-Line Treatment Of

Specjalistyczny Szpital im. dra Alfreda Sokolowskiego Poland has Released a tender for Delivery Of Drugs For A Non-Commercial Clinical Trial For The Experimental Arm Of Avo-Cll Financed By The Medical Research Agency As Part Of The Project Entitled "Avo-Cll Study: A Multicenter, Randomized, Open-Label, Phase 3 Study Comparing The Efficacy And Safety Of Acalabrutinib In Combination With Obinutuzumab Versus Venetoclax In Combination With Obinutuzumab In The First-Line Treatment Of in Pharmaceuticals. The tender was released on Jun 28, 2024.

Country - Poland

Summary - Delivery Of Drugs For A Non-Commercial Clinical Trial For The Experimental Arm Of Avo-Cll Financed By The Medical Research Agency As Part Of The Project Entitled "Avo-Cll Study: A Multicenter, Randomized, Open-Label, Phase 3 Study Comparing The Efficacy And Safety Of Acalabrutinib In Combination With Obinutuzumab Versus Venetoclax In Combination With Obinutuzumab In The First-Line Treatment Of

Deadline - login to view

MT reference number - 83416388

Product classification - Pharmaceutical products

Organization Details:

  Address - Poland

  Contact details - 565656565

  Tender notice no. - 76454545

  MT Ref Id - 83416388

  Document Type - Tender Notices

Notice Details and Documents:

Description - Description: The subject of the order is the supply of drugs for a non-commercial clinical trial for the experimental arm of AVO-CLL financed by the Medical Research Agency as part of the project entitled β€œThe AVO-CLL study: A multicenter, randomiz ed, open-label, phase 3 study comparing the efficacy and safety of acalabrutinib in combination with obinutuzumab versus venetoclax in combination with obinutuzumab in first-line treatment of newly diagnosed chronic lymphocytic leukemia.” A further and detailed description of the subject of the order can be found in Annex No. 1 to the Terms of Reference (hereinafter referred to as: SWZ).Package No. 1 – Doctor.Package No. 2 – Doctor.local ti

Mt Ref Id - 83416388

Deadline - Nov 30, -0001

Share

Similar Tenders :